InvestoGain Australia

SEARCH LISTED COMPANY

ANY AUS OR NZ COMPANY

BROWSE

Browse Australian listed companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

BROWSE

Browse Australian listed companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse Australian delisted companies/archived funds or use SEARCH

SEARCH PRIVATE COMPANY

SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

IMMURON LIMITED(IMC)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
IMMURON LIMITED05/12/2008
ANADIS LIMITED05/12/2008

Shareholder links

Our website ranking of IMC: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001

Tel : 1300 288 664 or +61 2 9698 5414
Fax : +61 2 8583 3040
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000IMC7
Address: Level 3 62 Lygon Street Carlton Vic 3053 Australia
Tel:  +61 (0) 3 9824 5254 Fax: +61 (0)3 9822 7735

Date first listed: 30/04/1999
Company Secretary: 
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: 

News & Events

Expand this box to read and print

The suspension of trading in the securities of Immuron Limited will be lifted from the commencement of trading on 24 September 2021, following the release by IMC of an announcement regarding a planned acquisition

23/09/2021

The Company has been pursuing a major acquisition of a private biotechnology company focused on the development of innovative vaccine technologies. After filing with the ASX a detailed ASX In-Principal Advice Application and subsequent lengthy discussions and exchanges with the ASX. ASX advised Immuron that based on the information provided to date, ASX does not currently have sufficient information to enable it to be satisfied that the combined group after the proposed acquisition would meet those requirements under chapters 1 and 2 of the ASX Listing Rules. Immuron as a result is now unable to satisfy the pre-conditions for this proposed acquisition due to the expiration of the existing contractual timetable and will not proceed with the proposed acquisition in its present form. There are no break fees associated with being unable to satisfy the preconditions existing contractual timetable, however professional fees associated with thistransaction over the past 4 months are approximately $450k plus GST.

23/09/2021

The company lodges its Preliminary Final Report.

31/08/2021

Immuron is required to lodge a formal In-Principle Advice Application in accordance with Guidance Note 12. That application has now been received by ASX, and the ASX is currently considering the application in connection with Immuron's suitability for admission to the official list of ASX Limited. Immuron acknowledges that its securities will remain suspended until it has met the requirements set out in Guidance Note 12.

07/07/2021

The company is limited in the detail that can be released at this time while the ASX consider a submission it has requested from the Company in relation to ASX Listing Rule 11.1 and 11.2 and Guidance Note 12.

08/06/2021

The securities of Immuron Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IMC, pending the release of an announcement regarding a planned acquisition.

31/05/2021

we understand that on or about this date the company consolidated its shares 1 for 40

17/11/2014

The suspension of trading in the securities of Immuron Limited (the "Company") will be lifted immediately, following the release of an announcement of a capital raising. Security Code: IMC

23/04/2012

The securities of Immuron Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a capital raising

20/04/2012

name changed from Anadis Limited

05/12/2008

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    Posting your comments. Please wait...

     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    30/06/2022Daniel Pollock50,000$0.076$3,800.00
    20/11/2020Daniel Pollock-100,000$0.260$26,000.00
    23/06/2020Daniel Pollock-100,000$0.325$32,500.00
    17/06/2020Peter Anastasiou-4,184,808$0.312$1,306,326.00
    11/06/2020Daniel Pollock-100,000$0.405$40,480.00

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Paul BrennanChairman16/03/2022
    Steven LydeamoreCEO27/06/2022
    Jerry KanellosCOO28/07/2015
    Jeannie JoughinNon Exec Director01/06/2024
    Daniel PollockNon Exec Director11/10/2012
    Ravi SavarirayanDirector07/04/2017
    Phillip HainsCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION

    Date of first appointment, title may have changed.